The global biopharmaceutical contract manufacturing sector is undergoing a rapid transition toward complex modalities as drug developers prioritize specialized treatments for metabolic and chronic conditions. In a major move to consolidate its position within the high-growth peptide market, Samsung Biologics has announced an all-cash public tender offer to acquire 100% of PolyPeptide Group AG. Valued at approximately CHF 1.46 billion, the transaction is designed to accelerate the South Korean giant’s multi-modality strategy by integrating specialized peptide expertise and an established global manufacturing network. The acquisition aims to create a differentiated, end-to-end multi-modality CDMO platform that can address the surging global demand for obesity and diabetes treatments, including GLP-1 therapies, which represent one of the fastest-growing segments in the industry today.
Under the terms of the offer announced on July 20, PolyPeptide shareholders will receive CHF 44.31 in cash per share. The deal has received unanimous support from PolyPeptide’s Board of Directors and an irrevocable tender undertaking from its largest shareholder, who represents approximately 55.65% of the outstanding shares. By combining Samsung Biologics’ massive manufacturing scale with PolyPeptide’s 70-year heritage in API production, the companies aim to serve a broader range of therapeutic indications, including oncology and other emerging areas. This strategic investment is intended to lay the foundation for the next phase of growth, positioning PolyPeptide for its next phase of growth as part of Samsung Biologics’ global multi-modality CDMO platform.
Geographic Expansion and Portfolio Diversification
The planned acquisition extends Samsung Biologics’ geographic reach into key pharmaceutical hubs across the United States, Europe, and India. PolyPeptide currently operates an integrated development-to-commercial model with facilities in Sweden, Belgium, France, the U.S., and India, supported by a corporate office in Switzerland and an innovation center in Strasbourg. This multi-site network is expected to enhance proximity to global clients and improve supply chain resilience for peptide-based active pharmaceutical ingredients (APIs). The modular and automation-focused approach of PolyPeptide’s manufacturing model provides the flexibility required to adapt to evolving market demands, particularly as peptide-based therapies continue to expand into new disease areas.
John Rim, Chairman and CEO of Samsung Biologics, emphasized the strategic value of the deal in terms of both capability and geography. “This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India,” Rim stated. “We highly value PolyPeptide’s world class employees, industry leading capabilities, and global operational footprint, and look forward to leveraging the complementary strengths of PolyPeptide and Samsung Biologics in our continued growth supporting clients as the CDMO of choice for decades to come.”
Strategic Rationale and Future Market Integration
The board of PolyPeptide determined that the transaction offers immediate value for shareholders while providing the scale necessary to lead the peptide therapeutics market. Peter Wilden, Chairman of the Board of PolyPeptide, noted that the merger represents a “transformational opportunity to accelerate our strategic ambitions at a scale we could not reach alone – creating a stronger global partner for customers and a platform uniquely positioned to lead the next phase of growth in peptide-based therapeutics.” The integration will bring together highly experienced scientific teams to enhance operational excellence and unlock new growth opportunities across the combined company’s pipeline of active peptide projects.
The tender offer is expected to launch by the end of August 2026, following a mandatory cooling-off period under Swiss takeover law. Completion of the transaction is slated for the end of 2026, subject to a minimum acceptance threshold of 66⅔% and customary regulatory approvals. Once successful, Samsung Biologics intends to pursue a squeeze-out of remaining minority shares and delist PolyPeptide from the SIX Swiss Exchange, transitioning it into a wholly owned subsidiary. This acquisition marks a significant step in the evolution of the CDMO landscape, as large-scale manufacturers increasingly seek to provide comprehensive, cross-modality services to the global biopharmaceutical industry.
